Celgene, Teva, others must face US antitrust claims over Revlimid, judge rules
A US judge ruled that Celgene, Teva, AbbVie, and others must face antitrust claims over alleged market monopolization of Revlimid. The judge found plausible evidence of an anticompetitive agreement between Celgene and Natco to delay a generic version, allowing high prices.
How this was made
The 30-second read
Why it matters
The ruling keeps the litigation alive, creating uncertainty for the involved companies.
Market read
The case could set a precedent for drug pricing enforcement, affecting pharma valuations.
What to watch
Potential settlement amounts and the effect on Natco's generic launch are not disclosed.
Background
US antitrust regulators are targeting alleged pay‑for‑delay agreements in the oncology drug market.
Ticker impact
Teva is named as a defendant in the US antitrust case over Revlimid.
downward pressure as market prices in antitrust risk
Judge's ruling keeps the case alive, suggesting possible fines or settlement costs.
AbbVie is listed among companies that must face US antitrust claims over Revlimid.
downward pressure due to potential legal costs and market uncertainty
The ruling indicates a plausible pay‑for‑delay scheme, raising risk for AbbVie.
Market effects
The biotech/pharma sector may see heightened scrutiny on drug pricing practices.
US pharma stocks could experience short‑term volatility.
International generic manufacturers may monitor the case for precedent.
Counterpoint
If the case stalls, the impact on stock prices could be limited.
Key entities
- companyCelgene
Original developer of Revlimid, now part of Bristol Myers Squibb.
- companyNatco
Indian generic manufacturer involved in the alleged agreement.
